A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma

NCT00502307 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

272

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: Tivozanib (AV-951)
DRUG: Placebo comparator

Sponsor

AVEO Pharmaceuticals, Inc.